(Total Views: 826)
Posted On: 04/23/2018 11:56:52 AM
Post# of 72447
Here's a company that was valued at 1.4 Billion. Their lead drug just failed, and their other two drugs are extremely unlikely to work (one person is quoted in the article as saying the probability of success is 0%).
https://endpts.com/prothenas-lead-drug-neod00...%20salvage
So, even after dropping over 62%, this company with a catastrophic clinical trial failure, and two drugs that are very unlikely to work, is still valued at FIVE HUNDRED AND FIFTY PERCENT the value of IPIX, with its 3 drugs that have have multiple clinical trial SUCCESSES.
Sheesh. Efficient markets, right.
https://endpts.com/prothenas-lead-drug-neod00...%20salvage
So, even after dropping over 62%, this company with a catastrophic clinical trial failure, and two drugs that are very unlikely to work, is still valued at FIVE HUNDRED AND FIFTY PERCENT the value of IPIX, with its 3 drugs that have have multiple clinical trial SUCCESSES.
Sheesh. Efficient markets, right.
(3)
(0)
